Direct Oral Anticoagulants (DOACs) Device Market Report 2025

The direct oral anticoagulants (DOACs) device market size has grown strongly in recent years. It will grow from $30.1 billion in 2024 to $32.8 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular disorders, increasing incidence of atrial fibrillation, growing awareness of stroke prevention, rising anticoagulant prescriptions, and the expanding geriatric population.

The direct oral anticoagulants (DOACs) device market size is expected to see strong growth in the next few years. It will grow to $45.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising preference for home-based anticoagulant management, growing demand for rapid diagnostic tools, expanding awareness of stroke prevention, and development of healthcare infrastructure in emerging markets. Major trends during this period include integration of smart sensors into monitoring devices, development of point-of-care direct oral anticoagulant testing tools, continuous innovation in drug delivery systems, incorporation into routine clinical workflows, and advancements in patient compliance technologies.

The rising prevalence of cardiovascular disorders is expected to drive the growth of the direct oral anticoagulants (DOACs) device market going forward. Cardiovascular disorders encompass conditions that affect the heart and blood vessels, often causing heart attacks, strokes, or other circulatory complications. The increase in these disorders is driven by increasingly sedentary lifestyles, which contribute to weight gain, high blood pressure, and weakened cardiovascular function over time. Direct oral anticoagulants (DOACs) help manage cardiovascular conditions by reducing the risk of stroke and blood clots in patients with atrial fibrillation, providing effective anticoagulation without frequent blood monitoring. For example, in January 2025, the American Heart Association, a US-based nonprofit organization, reported that cardiovascular disease caused 941,652 deaths in the US in 2022, an increase from 931,578 deaths in 2021. Therefore, the growing prevalence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.

Companies in the direct oral anticoagulants (DOACs) device market are developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of anticoagulant monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines to measure blood clotting speed, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched three coagulation tests designed specifically for Factor Xa inhibitors. These tests allow clinicians to accurately assess the anticoagulation status of patients taking rivaroxaban, apixaban, edoxaban, and heparin, supporting critical decisions during bleeding events, overdoses, or urgent surgeries. Using Roche’s reagent cassette technology on cobas t analyzers, these automated assays deliver reliable results, reduce manual handling, and optimize laboratory workflow efficiency.

In July 2024, Perosphere Technologies Inc., a US-based medical diagnostics company, partnered with CoRRect Medical to exclusively distribute its reagent-free point-of-care coagulometer in Germany. This partnership aims to meet unmet needs in coagulation testing by enabling rapid bedside assessment of anticoagulation status, particularly for patients on direct oral anticoagulants, improving treatment decisions, patient outcomes, and reducing healthcare costs. CoRRect Medical is a Germany-based medical device company.

Major players in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.

North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the direct oral anticoagulants (DOACs) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Direct oral anticoagulant (DOAC) devices are medical instruments or diagnostic tools designed to monitor and manage the blood-thinning effects of direct oral anticoagulant medications. These devices enable clinicians to assess anticoagulation status and drug levels in patients taking medications such as rivaroxaban, apixaban, edoxaban, or dabigatran, ensuring safe and effective therapy.

The primary products of DOAC devices include factor Xa inhibitors and direct thrombin inhibitors. Factor Xa inhibitors are anticoagulant medications that selectively block the activity of factor Xa, a key enzyme in the blood coagulation cascade, preventing the formation of harmful blood clots. They are commonly used to manage conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, heart attacks, and post-surgical thromboprophylaxis. Their applications cover stroke prevention, venous thromboembolism prevention, treatment of acute thrombotic events, long-term prophylaxis, and more. These devices are utilized by hospitals, ambulatory surgical centers, specialty clinics, homecare settings, and other healthcare providers.

The direct oral anticoagulants (DOACs) device market research report is one of a series of new reports that provides direct oral anticoagulants (DOACs) device market statistics, including direct oral anticoagulants (DOACs) device industry global market size, regional shares, competitors with a direct oral anticoagulants (DOACs) device market share, detailed direct oral anticoagulants (DOACs) device market segments, market trends and opportunities, and any further data you may need to thrive in the direct oral anticoagulants (DOACs) device industry. This direct oral anticoagulants (DOACs) device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The direct oral anticoagulants (DOACs) device market consists of sales of drug delivery devices, monitoring devices, adherence management tools and digital health platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.